Inhibitors: Avoid concurrent use with P-glycoprotein (P-gp) and strong CYP3A4 inhibitors. Dosage reduction is required when coadministered with P-gp and moderate CYP3A4 inhibitors.
Inducers: Dosage increase is required when coadministered with P-gp and strong CYP3A4 inducers.
Concurrent use may increase the risk of angioedema. Avoid concurrent use.
FDA,2022.02